Novocure Falls 5%, Zai Lab Rises 8%; Companies Report Study Results

By Josh Beckerman

Novocure Ltd. shares were down 5% to $80.59, and Zai Lab Ltd. American depositary receipts were up 8% at $30.86 after the companies reported results from a study of Tumor Treating Fields.

The EF-31 phase 2 pilot study tested Tumor Treating Fields together with standard-of-care (chemotherapy alone or in combination with trastuzumab for HER2-positive patients) in patients with gastric adenocarcinoma, the companies said.

The study met its primary endpoint of objective response rate with "supportive signals across secondary endpoints." The companies said the "outcomes are encouraging in a historically difficult-to-treat cancer."

Write to Josh Beckerman at [e-mail]

(END) Dow Jones Newswires

06-03-22 1309ET